All In Biotech

Drug Trial Radar · NCT05063253

A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Oct 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 208 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

208

Planned (sponsor's estimate)

Start

Oct 2021

Primary completion

Mar 2024

Study completion Mar 2024

Sponsor

Sponsor type
Industry
First posted
Oct 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the efficacy, safety, PK and PD characteristics of different doses of TG103 injection in overweight/obese subjects with type 2 diabetes mellitus.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • TG103Drug

    TG103 injection, SC, once weekly

  • PlaceboDrug

    Placebo, SC, once weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in glycosylated hemoglobin (HbA1c) from baseline to week 20Time frame: Baseline through Day 141 (the end of the 20-week treatment)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.